Titre : Syndrome de Li-Fraumeni

Syndrome de Li-Fraumeni : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement Activation
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Syndrome de Li-Fraumeni : Questions médicales les plus fréquentes", "headline": "Syndrome de Li-Fraumeni : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Syndrome de Li-Fraumeni : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-23", "dateModified": "2025-04-17", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Syndrome de Li-Fraumeni" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Troubles dus à un défaut de réparation de l'ADN", "url": "https://questionsmedicales.fr/mesh/D049914", "about": { "@type": "MedicalCondition", "name": "Troubles dus à un défaut de réparation de l'ADN", "code": { "@type": "MedicalCode", "code": "D049914", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "C18.452.284" } } }, "about": { "@type": "MedicalCondition", "name": "Syndrome de Li-Fraumeni", "alternateName": "Li-Fraumeni Syndrome", "code": { "@type": "MedicalCode", "code": "D016864", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Payal P Khincha", "url": "https://questionsmedicales.fr/author/Payal%20P%20Khincha", "affiliation": { "@type": "Organization", "name": "Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland." } }, { "@type": "Person", "name": "David Malkin", "url": "https://questionsmedicales.fr/author/David%20Malkin", "affiliation": { "@type": "Organization", "name": "Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, and Department of Pediatrics, University of Toronto, Toronto, Ontario." } }, { "@type": "Person", "name": "Sharon A Savage", "url": "https://questionsmedicales.fr/author/Sharon%20A%20Savage", "affiliation": { "@type": "Organization", "name": "Clinical Genetics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland." } }, { "@type": "Person", "name": "Allison Werner-Lin", "url": "https://questionsmedicales.fr/author/Allison%20Werner-Lin", "affiliation": { "@type": "Organization", "name": "School of Social Policy and Practice, University of Pennsylvania, Philadelphia, PA." } }, { "@type": "Person", "name": "Maria Isabel Achatz", "url": "https://questionsmedicales.fr/author/Maria%20Isabel%20Achatz", "affiliation": { "@type": "Organization", "name": "Centro de Oncologia, Hospital Sirio-Libanes, Rua Dona Adma Jafet, 115 - Bela Vista, São Paulo, Brazil." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Circulating Immune Complexes and Complement Activation in Sensitized Kidney Transplant Recipients.", "datePublished": "2024-10-10", "url": "https://questionsmedicales.fr/article/39456685", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3390/ijms252010904" } }, { "@type": "ScholarlyArticle", "name": "Tear fluid and complement activation products in tears after ocular surgery.", "datePublished": "2023-07-18", "url": "https://questionsmedicales.fr/article/37464366", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12886-023-03037-6" } }, { "@type": "ScholarlyArticle", "name": "Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis.", "datePublished": "2023-02-24", "url": "https://questionsmedicales.fr/article/36752022", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/ene.15730" } }, { "@type": "ScholarlyArticle", "name": "Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.", "datePublished": "2023-08-09", "url": "https://questionsmedicales.fr/article/37622108", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2023.1213920" } }, { "@type": "ScholarlyArticle", "name": "What complements complement in transplant-associated thrombotic microangiopathy?", "datePublished": "2022-08-09", "url": "https://questionsmedicales.fr/article/35942659", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1111/bjh.18402" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Maladies métaboliques et nutritionnelles", "item": "https://questionsmedicales.fr/mesh/D009750" }, { "@type": "ListItem", "position": 3, "name": "Maladies métaboliques", "item": "https://questionsmedicales.fr/mesh/D008659" }, { "@type": "ListItem", "position": 4, "name": "Troubles dus à un défaut de réparation de l'ADN", "item": "https://questionsmedicales.fr/mesh/D049914" }, { "@type": "ListItem", "position": 5, "name": "Syndrome de Li-Fraumeni", "item": "https://questionsmedicales.fr/mesh/D016864" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Syndrome de Li-Fraumeni - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Syndrome de Li-Fraumeni", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-07", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Syndrome de Li-Fraumeni", "description": "Comment est diagnostiqué le syndrome de Li-Fraumeni ?\nQuels tests génétiques sont utilisés ?\nQuels critères cliniques sont utilisés pour le diagnostic ?\nLe diagnostic peut-il être posé à tout âge ?\nLes tests de dépistage sont-ils recommandés ?", "url": "https://questionsmedicales.fr/mesh/D016864?mesh_terms=Complement+Activation&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Syndrome de Li-Fraumeni", "description": "Quels sont les symptômes du syndrome de Li-Fraumeni ?\nLes symptômes apparaissent-ils à un âge précoce ?\nY a-t-il des signes spécifiques à surveiller ?\nLes symptômes sont-ils toujours liés à des cancers ?\nLes symptômes peuvent-ils varier d'une personne à l'autre ?", "url": "https://questionsmedicales.fr/mesh/D016864?mesh_terms=Complement+Activation&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Syndrome de Li-Fraumeni", "description": "Comment prévenir le syndrome de Li-Fraumeni ?\nLes personnes à risque doivent-elles se faire dépister ?\nY a-t-il des recommandations pour les familles touchées ?\nLes habitudes de vie peuvent-elles influencer le risque ?\nLes tests génétiques sont-ils recommandés pour tous ?", "url": "https://questionsmedicales.fr/mesh/D016864?mesh_terms=Complement+Activation&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Syndrome de Li-Fraumeni", "description": "Quels traitements sont disponibles pour ce syndrome ?\nLa prévention des cancers est-elle possible ?\nLes traitements sont-ils différents selon le cancer ?\nY a-t-il des traitements expérimentaux disponibles ?\nLe suivi post-traitement est-il important ?", "url": "https://questionsmedicales.fr/mesh/D016864?mesh_terms=Complement+Activation&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Syndrome de Li-Fraumeni", "description": "Quelles complications peuvent survenir avec ce syndrome ?\nLes complications sont-elles prévisibles ?\nComment gérer les complications psychologiques ?\nLes complications peuvent-elles affecter la qualité de vie ?\nY a-t-il des complications spécifiques aux traitements ?", "url": "https://questionsmedicales.fr/mesh/D016864?mesh_terms=Complement+Activation&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Syndrome de Li-Fraumeni", "description": "Quels sont les principaux facteurs de risque ?\nLe mode de vie influence-t-il le risque ?\nLes femmes sont-elles plus à risque ?\nL'âge joue-t-il un rôle dans le risque ?\nLes facteurs environnementaux sont-ils impliqués ?", "url": "https://questionsmedicales.fr/mesh/D016864?mesh_terms=Complement+Activation&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment est diagnostiqué le syndrome de Li-Fraumeni ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique familial et des tests génétiques pour identifier des mutations." } }, { "@type": "Question", "name": "Quels tests génétiques sont utilisés ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests ciblent principalement les gènes TP53 et d'autres gènes associés au cancer." } }, { "@type": "Question", "name": "Quels critères cliniques sont utilisés pour le diagnostic ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les critères incluent des antécédents familiaux de cancers précoces et multiples." } }, { "@type": "Question", "name": "Le diagnostic peut-il être posé à tout âge ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le diagnostic peut être établi à tout âge, souvent après l'apparition de cancers." } }, { "@type": "Question", "name": "Les tests de dépistage sont-ils recommandés ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un dépistage régulier est conseillé pour détecter précocement les cancers." } }, { "@type": "Question", "name": "Quels sont les symptômes du syndrome de Li-Fraumeni ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes varient selon le type de cancer, incluant des douleurs, des masses et des changements de poids." } }, { "@type": "Question", "name": "Les symptômes apparaissent-ils à un âge précoce ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les cancers associés apparaissent souvent chez les jeunes adultes ou même les enfants." } }, { "@type": "Question", "name": "Y a-t-il des signes spécifiques à surveiller ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Surveillez les douleurs persistantes, les changements cutanés et les anomalies mammaires." } }, { "@type": "Question", "name": "Les symptômes sont-ils toujours liés à des cancers ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Pas toujours, mais tout symptôme persistant doit être évalué par un professionnel." } }, { "@type": "Question", "name": "Les symptômes peuvent-ils varier d'une personne à l'autre ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'expression des symptômes peut varier en fonction des cancers développés." } }, { "@type": "Question", "name": "Comment prévenir le syndrome de Li-Fraumeni ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de prévention, mais un dépistage régulier peut aider à détecter les cancers tôt." } }, { "@type": "Question", "name": "Les personnes à risque doivent-elles se faire dépister ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes à risque élevé doivent suivre un programme de dépistage régulier." } }, { "@type": "Question", "name": "Y a-t-il des recommandations pour les familles touchées ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les familles doivent consulter des conseillers en génétique pour des recommandations personnalisées." } }, { "@type": "Question", "name": "Les habitudes de vie peuvent-elles influencer le risque ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Adopter un mode de vie sain peut réduire le risque de certains cancers, mais pas tous." } }, { "@type": "Question", "name": "Les tests génétiques sont-ils recommandés pour tous ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Non, ils sont recommandés principalement pour les personnes ayant des antécédents familiaux." } }, { "@type": "Question", "name": "Quels traitements sont disponibles pour ce syndrome ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent la chirurgie, la chimiothérapie et la radiothérapie selon le cancer." } }, { "@type": "Question", "name": "La prévention des cancers est-elle possible ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Une surveillance régulière et des interventions précoces peuvent aider à prévenir certains cancers." } }, { "@type": "Question", "name": "Les traitements sont-ils différents selon le cancer ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, chaque type de cancer peut nécessiter un traitement spécifique adapté." } }, { "@type": "Question", "name": "Y a-t-il des traitements expérimentaux disponibles ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Des essais cliniques peuvent offrir des options de traitement innovantes pour les patients." } }, { "@type": "Question", "name": "Le suivi post-traitement est-il important ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, un suivi régulier est crucial pour détecter toute récidive ou nouveaux cancers." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec ce syndrome ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des cancers multiples, des effets secondaires des traitements et des problèmes psychologiques." } }, { "@type": "Question", "name": "Les complications sont-elles prévisibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être anticipées, mais d'autres peuvent survenir de manière inattendue." } }, { "@type": "Question", "name": "Comment gérer les complications psychologiques ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Un soutien psychologique et des groupes de soutien peuvent aider à gérer l'anxiété et la dépression." } }, { "@type": "Question", "name": "Les complications peuvent-elles affecter la qualité de vie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications liées aux traitements et aux cancers peuvent altérer la qualité de vie." } }, { "@type": "Question", "name": "Y a-t-il des complications spécifiques aux traitements ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent entraîner des effets secondaires comme la fatigue, la nausée et l'immunosuppression." } }, { "@type": "Question", "name": "Quels sont les principaux facteurs de risque ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les antécédents familiaux de cancers et les mutations génétiques, notamment TP53, sont des facteurs clés." } }, { "@type": "Question", "name": "Le mode de vie influence-t-il le risque ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des facteurs comme le tabagisme et l'alimentation peuvent influencer le risque de cancer." } }, { "@type": "Question", "name": "Les femmes sont-elles plus à risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Non, le syndrome affecte également les hommes, bien que certains cancers soient plus fréquents chez les femmes." } }, { "@type": "Question", "name": "L'âge joue-t-il un rôle dans le risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le risque de développer des cancers augmente avec l'âge, surtout après 30 ans." } }, { "@type": "Question", "name": "Les facteurs environnementaux sont-ils impliqués ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Des facteurs environnementaux peuvent contribuer au risque, mais le syndrome est principalement génétique." } } ] } ] }

Sources (10000 au total)

Tear fluid and complement activation products in tears after ocular surgery.

Due to technological advancements, surgical invasiveness has been reduced. However, cataract surgery has been implicated in causing postoperative inflammation, including dry eye syndrome. The innate i... Forty-three patients (23 women; median age, 69 years) were enrolled in this prospective study and underwent phacoemulsification and vitrectomy. We measured Schirmer's test (ST) and CAPs in the tears a... The median ST (8.5 mm) at baseline increased to 16 mm at 4 days ( P < 0.001) and 10 mm at 1 month (P = 0.44). The C3a levels (1202 pg/ml) at baseline increased to 2753 pg/ml at 4 days (P < 0.001), and... The CAPs levels in tears increased after vitrectomy combined with cataract surgery. A preoperative deficit in tear secretion might induce prolonged complement activation and delayed recovery of ocular...

Complement activation profiles in anti-acetylcholine receptor positive myasthenia gravis.

Complement component 5 (C5) targeting therapies are clinically beneficial in patients with acetylcholine receptor antibody... In a case-control study, concentrations of C3a, C5a and sC5b9 were simultaneously quantified, indicating general activation of the complement system, whether via the classical and lectin pathways (C4a... Treatment-naïve patients with AChR-Ab... Markers indicative of complement activation are prominently increased in patients with AChR-Ab MG despite standard immunosuppressive therapies. Complement inhibition proximal to C5 cleavage should be ...

Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.

The complement system is a key component of the innate immune system, and its aberrant activation underlies the pathophysiology of various diseases. Zilucoplan is a macrocyclic peptide that binds and ... The interaction of zilucoplan with C5, including for clinical C5 R885 variants, was investigated using surface plasmon resonance (SPR), hemolysis assays, and ELISA. The interference of C5b6 formation ... Zilucoplan specifically bound human complement C5 with high affinity, competitively inhibited the binding of C5 to C3b, and blocked C5 cleavage by C5 convertases and the assembly of the cytolytic memb... Our findings demonstrate that zilucoplan uses a dual mode of action to potently inhibit the activation of C5 and terminal complement pathway including wild-type and clinical R885 variants that do not ...

Impact of neutrophil extracellular traps on fluid properties, blood flow and complement activation.

The intravascular formation of neutrophil extracellular traps (NETs) is a trigger for coagulation and blood vessel occlusion. NETs are released from neutrophils as a response to strong inflammatory si... In the present study, we used different microfluidic setups in combination with fluorescence microscopy to investigate the influence of neutrophil-derived extracellular DNA fibers on blood rheology, i... We found that extended DNA fiber networks decelerate blood flow and promote intravascular occlusion of blood vessels independent of the plasmatic coagulation. Associated with the DNA dependent occlusi... In conclusion, we found that DNA fibers as the principal component of NETs are sufficient to induce blood aggregation even in the absence of the coagulation system. Moreover, we discovered that comple...

Complement activation in severely ill patients with sepsis: no relationship with inflammation and disease severity.

Sepsis is characterized by a dysregulated immune response to infection. The complement system plays an important role in the host defence to pathogens. However, exaggerated complement activation might... Secondary analysis of complement factors in a prospective study in 209 hospitalized sepsis patients, of whom the majority presented with shock. Concentrations of complement factors C3, C3a, C3c, C5, C... The concentration of complement factors in plasma of severely ill sepsis patients indicated profound activation of the complement system (all P < 0.01 compared to healthy controls). Spearman rank corr... Once an infection progresses to severe sepsis or septic shock, the complement pathway is already profoundly activated and is no longer related to a dysregulated inflammatory response, nor to clinical ...

Role of Surface Charge of Nanoscale Ultrasound Contrast Agents in Complement Activation and Phagocytosis.

To prepare nanoscale ultrasound contrast agents (Nano-UCAs) and examine the role of their surface charge in complement activation and phagocytosis.... We analyzed serum proteins present in the corona formed on Nano-UCAs and evaluated two important protein markers of complement activation (C3 and SC5b-9). The effect of surface charge on phagocytosis ... When Nano-UCAs were incubated with human serum, they were opsonized by various blood proteins, especially C3. Highly charged Nano-UCAs, whether positive or negative, were favorably opsonized by comple... Charged Nano-UCAs show a higher tendency to activated complement system, and are efficiently engulfed by macrophages. The present results provide meaningful insights into the role of the surface charg...